that Synta has such little activity and name recognition from the general biotech blogosphere, while many other biotech message boards have dozens or even hundreds of posts daily. Synta is basically an unknown company to most retail investors....despite having a potentially BLOCKBUSTER cancer drug--ganetespib-- deep in the pipeline (and it may turn out to be one of the most important versatile cancer drugs of all time)...
I think that by this time in 2014, everyone in the biotech investing world will be talking about Synta, as it becomes the next PCYC or MDVN
You do realize many experts feel the data is not real. Not short, just had to step to the sideline because history has a way of repeating itself. Raging battle inside because I want to believe like you do.
Every single upstart biotech I have followed or owned has had the same bull/bear battles. Saw it in Medimmune, GILD, CELG, ONXX along with many more and all of the aforementioned turned out to be GIGANTIC winners.
Do your DD as best you can in trying to figure out the equation. As for me, I am buying because I see a smart man like Mr. Kovner taking a position, regardless of how small of an investment it is for him. Could he write off the loss if he is wrong? Sure he can but I guarantee that he would rather pay the capital gains on a nice winner.